相关实验视频

Updated: Jan 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在HER2-阳性乳腺癌中重新评估治疗反应分层

Bilal Turan¹, Ahmet Necati Sanli², Deniz Esin Tekcan Sanli³

¹Department of General Surgery, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.

The American surgeon

|September 19, 2025

概括

将HER2阳性乳腺癌反应分为完全响应 (CR),部分响应 (PR) 和无响应 (NR) 的分类可以改善生存预测. 部分响应者比非响应者有更好的结果,指导个性化治疗.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
临床预后临床预后

背景情况:

新辅助化疗 (NAC) 反应对HER2阳性乳腺癌预后至关重要.
当前的模型经常将不完整的反应组合在一起,可能会缺失预后差异.
在HER2阳性乳腺癌中,部分反应 (PR) 可能代表一个独特的预后类别.

研究的目的:

评估HER2阳性乳腺癌中NAC反应的三方分类 (CR,PR,NR) 的预后价值.
为了比较CR,PR和NR组之间的生存结果.
在这个患者群体中确定生存的预测因素.

主要方法:

使用国家癌症登记册进行的回顾性队列研究.
对4711名HER2阳性女性乳腺癌患者的分析,这些患者接受了NAC治疗.
将其分为CR,PR和NR组;评估使用卡普兰-梅尔和考克斯回归的整体生存率 (OS) 和疾病特异性生存率 (DSS).

主要成果:

CR: 72.4%,PR: 24.9%,NR: 2.8%. 这是一个很大的问题.
与NR组 (35.5%) 相比,PR组的10年生存率 (74.7%) 和DSS显著更高.
多变量分析证实,PR独立地与比NR更好的生存率相关 (HR OS: 2.51,HR DSS: 2.75).

结论:

三方分类 (CR,PR,NR) 为 HER2 阳性乳腺癌的二元模型提供了优越的预后歧视.
部分响应者代表了一个独特的临床群体,其生存结果有所改善.
这种精细的分类可以提高风险分层和个性化NAC后治疗计划.

关键词:

在HER2阳性乳腺癌中,HER2是阳性乳腺癌.新辅助性化疗是一种新辅助性化疗.部分反应的部分反应.生存分析,生存分析.治疗反应治疗反应.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...